Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Pediatric Hematology/Oncology
•
Leukemia
•
ALL
What are the recommended treatment options for patients with infant ALL and KMT2A rearrangement who relapse during therapy?
Related Questions
How do you manage severe hypertriglyceridemia in the adolescent & young adult population receiving chemotherapy for ALL, in the absence of complications related to hypertriglyceridemia?
For a pediatric patient with B-ALL who requires surgery during maintenance, what therapy modifications do you recommend to allow for optimal healing and minimal treatment disruption?
Do you check asparaginase levels for all patients receiving receiving E. coli-derived products, or only in certain clinical situations?
Would you offer intensive CNS prophylaxis to Ph negative B-ALL patients who have possible mandibular nerve involvement on MRI face?
How would you manage an early isolated CNS relapse in a pediatric patient with Ph positive ALL?
How do you incorporate blinatumomab into therapy for a pediatric or AYA patient with isolated CNS relapse of B-ALL, if at all?
In what situations do you use G-CSF for patients undergoing allogeneic HSCT to facilitate engraftment?
What is the preferred approach for an AYA patient with VHR B-ALL with iAMP21 mutation with an isolated early CNS relapse?
How do you address logistic barriers related to blinatumomab when treating relapsed B-ALL?
Does the presence of asparaginase antibodies on Granger Genetics testing indicate need to switch asparaginase formulations?
